Squarepoint
AVBP icon

Squarepoint’s ArriVent BioPharma AVBP Stock Holding History

Squarepoint’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$609K Sell
17,544
-37,888
-68% -$1.12M ﹤0.01% 3270
2026
Q1 		$1.28M Sell
55,432
-131,060
-70% -$2.96M ﹤0.01% 2566
2025
Q4 		$3.75M Buy
186,492
+58,185
+45% +$1.21M ﹤0.01% 1641
2025
Q3 		$2.37M Sell
128,307
-76,048
-37% -$1.49M ﹤0.01% 1961
2025
Q2 		$4.45M Buy
204,355
+185,929
+1,009% +$3.86M ﹤0.01% 1539
2025
Q1 		$341K Buy
+18,426
New +$451K ﹤0.01% 3640

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Squarepoint's AVBP Position: Q2 2026 in Review

Squarepoint reduced its ArriVent BioPharma (AVBP) stake by 68% in Q2 2026, selling an estimated $1.12M and leaving 17,544 shares worth $609K. The position accounts for ﹤0.01% of the portfolio, ranked #3270.

Squarepoint first reported a position in AVBP in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.45M in Q2 2025. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Squarepoint held 17,544 shares of ArriVent BioPharma worth $609K as of Q2 2026.
  • Squarepoint sold 37,888 ArriVent BioPharma shares in Q2 2026, an estimated $1.12M.
  • ArriVent BioPharma made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3270 holding.
  • Squarepoint first reported a position in ArriVent BioPharma in Q1 2025 and has held it in 6 quarters since.
  • Squarepoint's ArriVent BioPharma position peaked at $4.45M in Q2 2025.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.